NASDAQ$ANIP
ANI Pharmaceuticals Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
ANI Pharmaceuticals reported record fourth quarter 2025 net revenues and earnings, driven by strong Rare Disease and Generics growth.
ANI delivered record Q4 2025 revenue of 247060000, up 29.6% year-over-year, with strong Cortrophin Gel and Generics growth driving profitability. Net income available to common shareholders was 27490000 and adjusted non-GAAP EBITDA rose 30.6% to 65356000.
- Total net revenues increased 29.6% year-over-year to 247060000.
- Cortrophin Gel revenue grew 87.6% to 111431000.
- Generics revenue increased 28.2% to 100760000.
- Adjusted non-GAAP EBITDA rose 30.6% to 65356000.
Headline financials
Revenue & EPS history
ANI Pharmaceuticals · Revenue · Quarterly
$247M
Revenue by segment
ANI Pharmaceuticals · $57.6M total across 2 segments · Q1 2022
- Generic Products$49.1M+48.8%85.2%
- Brands$8.5M+13.3%14.8%
Forward guidance
ANI reaffirmed full year 2026 guidance, expecting continued growth in revenue and adjusted EBITDA driven by Rare Disease expansion and Generics execution.
Tailwinds
- 2026 total net revenue guidance of 1055000000 to 1115000000.
- Cortrophin Gel 2026 revenue guidance of 540000000 to 575000000.
- Adjusted non-GAAP EBITDA guidance of 275000000 to 290000000.
- Adjusted non-GAAP diluted EPS guidance of 8.83 to 9.34.
- Expected total company adjusted non-GAAP gross margin between 59.3% and 60.3%.
Headwinds
- Brands revenue declined 37.9% year-over-year in Q4.
- Selling, general and administrative expenses increased 18.7% year-over-year.
- Non-GAAP gross margin declined year-over-year due to product mix.
- Litigation expenses impacted adjusted results.
- Interest expense of 4411000 in the quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
-1.2%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.7%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+52.1%
Q3 2021
Best reaction
-24.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | -3.7% | — | |
| Q4 2025 | -3.9% | -0.8% | -5.6% | |
| Q3 2025 | +0.4% | -3.3% | -9.4% | |
| Q1 2025 | -7.5% | -15.6% | -13.4% | |
| Q4 2024 | +13.4% | +6.3% | +10.7% | |
| Q3 2024 | +5.8% | +2.5% | -2.4% | |
| Q2 2024 | -3.6% | -2.1% | +2.7% | |
| Q1 2024 | +2.2% | -1.6% | +1.3% | |
| Q4 2023 | +11.4% | -0.2% | +3.0% | |
| Q3 2023 | -17.9% | -18.8% | -23.1% | |
| Q2 2023 | +8.4% | +9.2% | +10.7% | |
| Q1 2023 | +13.5% | +6.5% | +26.2% | |
| Q4 2022 | -5.3% | -6.0% | -11.5% | |
| Q3 2022 | -5.1% | -4.7% | +3.2% | |
| Q2 2022 | -1.8% | +8.2% | +7.3% | |
| Q1 2022 | -5.9% | +1.3% | +6.9% | |
| Q4 2021 | -24.6% | -23.6% | -9.8% | |
| Q3 2021 | +52.1% | +33.8% | +8.2% | |
| Q2 2021 | -7.9% | -8.5% | -11.5% | |
| Q1 2021 | -6.0% | -4.1% | -1.8% | |
| Q4 2020 | +4.1% | +6.6% | +5.3% | |
| Q3 2020 | -15.9% | -3.5% | +4.1% | |
| Q2 2020 | -2.0% | +0.7% | -6.0% | |
| Q1 2020 | -7.0% | -12.1% | -13.0% | |
| Q4 2019 | -19.1% | -8.1% | -41.2% | |
| Q3 2019 | -22.2% | -27.3% | -24.7% | |
| Q2 2019 | -10.8% | -13.7% | -21.0% | |
| Q1 2019 | +3.1% | -1.7% | -0.3% | |
| Q4 2018 | +7.7% | +0.1% | +8.6% | |
| Q3 2018 | +7.2% | +2.1% | -0.2% | |
| Q2 2018 | -13.0% | -13.1% | -13.7% | |
| Q1 2018 | +3.9% | +3.9% | +9.6% | |
| Q4 2017 | +11.3% | -3.8% | +0.6% | |
| Q3 2017 | +7.7% | +4.2% | +22.8% | |
| Q2 2017 | -2.9% | -3.8% | +6.3% | |
| Q1 2017 | -2.0% | +0.7% | -10.3% | |
| Q4 2016 | -16.3% | -18.0% | -17.2% | |
| Q3 2016 | -18.8% | -18.0% | -2.1% | |
| Q2 2016 | +10.0% | +12.6% | -3.6% | |
| Q1 2016 | +6.4% | — | — | |
| Q4 2015 | +9.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -14.0% | — | — | |
| Q1 2015 | -15.4% | — | — | |
| Q4 2014 | +4.0% | — | — | |
| Q3 2014 | +27.1% | — | — | |
| Q2 2014 | +9.7% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q2 2013 | -3.0% | — | — | |
| Q4 2013 | +24.9% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -0.8% | — | — | |
| Q2 2012 | -15.5% | — | — | |
| Q1 2012 | -15.4% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q4 2009 | +0.0% | — | — | |
| Q3 2011 | -6.0% | — | — | |
| Q4 2010 | -7.2% | — | — | |
| Q2 2010 | -7.2% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q3 2010 | -6.3% | — | — | |
| Q1 2010 | -5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro